Phase 2 Chronic Low Back Pain Study
CompletedPhase 2NCT01364922
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The primary purpose of this study was to evaluate the analgesic effect and safety of hydrocodone/acetaminophen extended release compared to placebo.
Study details
- Official title
- A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of Hydrocodone/Acetaminophen Extended Release Compared to Placebo in Subjects With Chronic Low Back Pain
- Conditions
- Interventions
- Drug: hydrocodone/acetaminophen extended release
- Drug: Placebo
- Sponsor
- AbbVie (prior sponsor, Abbott)
- Organization
- AbbVie
- Start date
- 2011-06
- Primary completion
- 2011-10
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 17
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: Adult subjects who have a diagnosis of chronic low back pain of at least 6 month duration Exclusion Criteria: Subjects with a history of surgical or invasive intervention
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01364922